Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 08, 2023

BUY
$23.85 - $31.34 $16,981 - $22,314
712 Added 5.73%
13,148 $385,000
Q4 2022

Feb 07, 2023

BUY
$17.65 - $27.37 $59,092 - $91,634
3,348 Added 36.84%
12,436 $327,000
Q3 2022

Nov 01, 2022

BUY
$22.62 - $32.54 $927 - $1,334
41 Added 0.45%
9,088 $211,000
Q2 2022

Aug 04, 2022

BUY
$22.88 - $39.45 $44,204 - $76,217
1,932 Added 27.15%
9,047 $228,000
Q1 2022

May 09, 2022

BUY
$31.69 - $43.29 $11,820 - $16,147
373 Added 5.53%
7,115 $272,000
Q4 2021

Feb 07, 2022

BUY
$35.2 - $52.6 $26,892 - $40,186
764 Added 12.78%
6,742 $277,000
Q2 2021

Aug 06, 2021

SELL
$47.2 - $67.81 $402,852 - $578,758
-8,535 Reduced 58.81%
5,978 $314,000
Q1 2021

May 06, 2021

BUY
$30.93 - $59.48 $144,412 - $277,712
4,669 Added 47.43%
14,513 $806,000
Q4 2020

Feb 09, 2021

SELL
$18.53 - $31.5 $60,241 - $102,406
-3,251 Reduced 24.83%
9,844 $304,000
Q3 2020

Nov 10, 2020

BUY
$14.68 - $19.12 $2,084 - $2,715
142 Added 1.1%
13,095 $243,000
Q2 2020

Aug 06, 2020

BUY
$8.5 - $15.82 $31,841 - $59,261
3,746 Added 40.69%
12,953 $179,000
Q1 2020

May 11, 2020

BUY
$7.25 - $19.22 $12,825 - $34,000
1,769 Added 23.78%
9,207 $84,000
Q4 2019

Feb 05, 2020

SELL
$13.77 - $19.2 $25,116 - $35,020
-1,824 Reduced 19.69%
7,438 $128,000
Q3 2019

Nov 12, 2019

BUY
$14.93 - $19.83 $24,156 - $32,084
1,618 Added 21.17%
9,262 $140,000
Q2 2019

Aug 08, 2019

SELL
$15.01 - $18.89 $29,869 - $37,591
-1,990 Reduced 20.66%
7,644 $144,000
Q1 2019

Apr 26, 2019

BUY
$16.23 - $20.29 $16,343 - $20,432
1,007 Added 11.67%
9,634 $169,000
Q4 2018

Feb 08, 2019

SELL
$10.77 - $18.44 $16,682 - $28,563
-1,549 Reduced 15.22%
8,627 $141,000
Q3 2018

Nov 13, 2018

BUY
$9.1 - $14.8 $92,601 - $150,604
10,176 New
10,176 $144,000

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.76B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.